{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:44:39Z","timestamp":1793202279986,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European League Against Rheumatism","doi-asserted-by":"publisher","award":["QoC015"],"award-info":[{"award-number":["QoC015"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1136\/ard-2023-225319","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T17:15:23Z","timestamp":1716398123000},"page":"1489-1501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8832-7475","authenticated-orcid":false,"given":"Myrto","family":"Kostopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9771-6667","authenticated-orcid":false,"given":"Chetan B","family":"Mukhtyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5299-1406","authenticated-orcid":false,"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-4671","authenticated-orcid":false,"given":"Dimitrios T","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-031X","authenticated-orcid":false,"given":"Antonis","family":"Fanouriakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-225319_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-225319_bib3","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib4","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-225319_bib5","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"The Lancet"},{"key":"10.1136\/ard-2023-225319_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib8","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1177\/09612033221129774","article-title":"Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: a systematic review and meta-analysis of cohort studies","volume":"31","author":"Cai","year":"2022","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225319_bib9","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"Update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1136\/ard-2023-225319_bib11","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.2022.13591","article-title":"Hydroxychloroquine dose per ophthalmology guidelines and the risk of systemic lupus erythematosus flares","volume":"328","author":"Jorge","year":"2022","journal-title":"JAMA"},{"key":"10.1136\/ard-2023-225319_bib12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/acr.24592","article-title":"Medium versus high initial prednisone dose for remission induction in lupus nephritis: a propensity score-matched analysis","volume":"74","author":"Tselios","year":"2022","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2023-225319_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/1756-185X.14265","article-title":"Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients","volume":"25","author":"Bandhan","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/ijn.IJN_299_18","article-title":"Comparison of two steroid regimens in induction therapy of proliferative lupus nephritis: a randomized controlled trial","volume":"29","author":"Bharati","year":"2019","journal-title":"Indian J Nephrol"},{"key":"10.1136\/ard-2023-225319_bib15","article-title":"Belimumab for systemic lupus erythematosus","volume":"2","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ard-2023-225319_bib16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III \/ IV, randomized, Fifty\u2010Two \u2013week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of Belimumab in patients with systemic lupus erythematosus located in China","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib18","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2665-9913(20)30355-6","article-title":"Mortality and adverse events of special interest with intravenous Belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial","volume":"3","author":"Sheikh","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib19","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1177\/09612033221131183","article-title":"Safety of belimumab in adult patients with systemic lupus erythematosus: results of a large integrated analysis of controlled clinical trial data","volume":"31","author":"Wallace","year":"2022","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225319_bib20","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1177\/0961203320959702","article-title":"Biologics targeting type I Interferons in SLE: a meta-analysis and systematic review of randomised controlled trials","volume":"29","author":"Koh","year":"2020","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225319_bib21","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/09612033211014267","article-title":"Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus","volume":"30","author":"Furie","year":"2021","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225319_bib22","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib23","doi-asserted-by":"crossref","first-page":"996662","DOI":"10.3389\/fimmu.2022.996662","article-title":"Evaluation of anifrolumab safety in systemic lupus erythematosus: a meta-analysis and systematic review","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-225319_bib24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo\u2010controlled phase iii extension trial of the long\u2010term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib25","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib26","doi-asserted-by":"crossref","first-page":"e000459","DOI":"10.1136\/lupus-2020-000459","article-title":"Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme","volume":"8","author":"Maslen","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-225319_bib27","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/acr.25058","article-title":"Improvement in cutaneous lupus erythematosus after twenty weeks of Belimumab use: a systematic review and Meta\u2010Analysis","volume":"75","author":"Kneeland","year":"2023","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2023-225319_bib28","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.41253","article-title":"Early disease and low baseline damage as predictors of response to Belimumab in patients with systemic lupus erythematosus in a Real\u2010Life setting","volume":"72","author":"Gatto","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.autrev.2017.02.005","article-title":"Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus","volume":"16","author":"Parodis","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2023-225319_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/acr.22971","article-title":"Effects of Belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus","volume":"69","author":"Iaccarino","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2023-225319_bib31","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib32","doi-asserted-by":"crossref","first-page":"e000284","DOI":"10.1136\/lupus-2018-000284","article-title":"Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus","volume":"5","author":"Merrill","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-225319_bib33","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1177\/0961203320947814","article-title":"Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: results from a 24-month observe study in Argentina","volume":"29","author":"Babini","year":"2020","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225319_bib34","first-page":"415","article-title":"Belimumab is able to induce a significant improvement of joint activity status in patients diagnosed with systemic lupus erythematosus: results from a 12-month longitudinal study","volume":"22","author":"Ceccarelli","year":"2020","journal-title":"Isr Med Assoc J"},{"key":"10.1136\/ard-2023-225319_bib35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5152\/eurjrheum.2018.17096","article-title":"Outcomes of rituximab therapy in refractory lupus: a meta-analysis","volume":"5","author":"Alshaiki","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12882-018-0973-7","article-title":"Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial","volume":"19","author":"Sedhain","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1136\/ard-2023-225319_bib37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00296-018-3995-3","article-title":"Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study","volume":"38","author":"Mehra","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2023-225319_bib38","doi-asserted-by":"crossref","first-page":"e224492","DOI":"10.1001\/jamanetworkopen.2022.4492","article-title":"Effect of tacrolimus vs intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis: a randomized clinical trial","volume":"5","author":"Zheng","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ard-2023-225319_bib39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/0961203317739131","article-title":"Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial","volume":"27","author":"Kamanamool","year":"2018","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225319_bib40","first-page":"687","article-title":"Clinical analysis of multi-target treatment for complex lupus nephritis","volume":"14","author":"Ye","year":"2022","journal-title":"Am J Transl Res"},{"key":"10.1136\/ard-2023-225319_bib41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2023-225319_bib42","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","article-title":"Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis","volume":"79","author":"Mok","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib43","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2147\/DDDT.S189156","article-title":"Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis","volume":"13","author":"Zhou","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1136\/ard-2023-225319_bib44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000525066","article-title":"Comparative efficacy and safety of tacrolimus, cyclosporin a, mycophenolate mofetil, cyclophosphamide, and corticosteroids as induction therapy for membranous lupus nephritis: a network meta-analysis","volume":"107","author":"Lee","year":"2022","journal-title":"Pharmacology"},{"key":"10.1136\/ard-2023-225319_bib45","doi-asserted-by":"crossref","first-page":"859380","DOI":"10.3389\/fimmu.2022.859380","article-title":"Comparative effectiveness of rituximab and common induction therapies for lupus nephritis: a systematic review and network meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-225319_bib46","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/acr.25007","article-title":"Update on the efficacy and safety profile of Voclosporin: an integrated analysis of clinical trials in lupus nephritis","volume":"75","author":"Arriens","year":"2023","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2023-225319_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long\u2010term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib48","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2023-225319_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib50","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib52","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2022-222486","article-title":"Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up","volume":"81","author":"Fu","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib53","doi-asserted-by":"crossref","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","article-title":"DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-225319_bib54","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib55","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","article-title":"Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial","volume":"79","author":"Mathian","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib56","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1093\/rheumatology\/keab149","article-title":"Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual","volume":"60","author":"Ji","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-225319_bib57","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/annrheumdis-2021-221295","article-title":"Flares after hydroxychloroquine reduction or discontinuation: results from the systemic lupus International collaborating clinics (SLICC) inception cohort","volume":"81","author":"Almeida-Brasil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib58","doi-asserted-by":"crossref","first-page":"152046","DOI":"10.1016\/j.semarthrit.2022.152046","article-title":"Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus","volume":"55","author":"Papachristos","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-225319_bib59","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/acr.24548","article-title":"Predictors of unsuccessful hydroxychloroquine tapering and discontinuation: can we personalize decision\u2010making in systemic lupus erythematosus treatment","volume":"74","author":"Almeida\u2010Brasil","year":"2022","journal-title":"Arthritis Care & Research"},{"key":"10.1136\/ard-2023-225319_bib60","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","article-title":"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-lupus): results of a multicentre randomised controlled trial","volume":"81","author":"Jourde-Chiche","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib61","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/rheumatology\/keab373","article-title":"Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis","volume":"61","author":"Zen","year":"2022","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2023-225319_bib62","doi-asserted-by":"crossref","first-page":"e000574","DOI":"10.1136\/lupus-2021-000574","article-title":"Herpes Zoster in SLE: prevalence, incidence and risk factors","volume":"9","author":"Kwan","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-225319_bib63","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11926-023-01110-z","article-title":"Systemic lupus erythematosus and COVID-19","volume":"25","author":"Pappa","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/ard-2023-225319_bib64","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the Zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center's experience with 400 patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib65","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2023-225319_bib66","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/art.42261","article-title":"Recombinant zoster vaccine uptake and risk of flares among older adults with immune\u2010mediated inflammatory diseases in the US","volume":"74","author":"Leung","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib67","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1136\/annrheumdis-2019-215925","article-title":"Safety and immune response of a live-attenuated herpes Zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial","volume":"78","author":"Mok","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib68","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/rheumatology\/keac604","article-title":"COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, Immunogenicity, flares and acceptance","volume":"62","author":"Tan","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-225319_bib69","doi-asserted-by":"crossref","first-page":"e000516","DOI":"10.1136\/lupus-2021-000516","article-title":"LUPUS-BEST\u2014treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial","volume":"8","author":"Mucke","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-225319_bib70","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s43162-021-00047-y","article-title":"Frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus","volume":"33","author":"Abdelbaky","year":"2021","journal-title":"Egypt J Intern Med"},{"key":"10.1136\/ard-2023-225319_bib71","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.41121","article-title":"Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy","volume":"72","author":"Petri","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib72","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1346-8138.14802","article-title":"Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients","volume":"46","author":"Ototake","year":"2019","journal-title":"J Dermatol"},{"key":"10.1136\/ard-2023-225319_bib73","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0961203319829826","article-title":"Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus","volume":"28","author":"Mart\u00edn-Iglesias","year":"2019","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225319_bib74","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/rheumatology\/keaa157","article-title":"Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis","volume":"59","author":"Lenfant","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-225319_bib75","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1089\/jop.2022.0060","article-title":"Characteristics and potential risk factors of hydroxychloroquine retinopathy in patients with systemic lupus erythematosus: focusing on Asian population","volume":"38","author":"Kao","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1136\/ard-2023-225319_bib76","doi-asserted-by":"crossref","first-page":"e000789","DOI":"10.1136\/lupus-2022-000789","article-title":"Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine","volume":"9","author":"Almeida-Brasil","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-225319_bib77","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1177\/09612033221115618","article-title":"Why lupus patients discontinue antimalarials in real life: a 50 years-experience from a reference centre","volume":"31","author":"Ara\u00fajo","year":"2022","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225319_bib78","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/0961203317742712","article-title":"Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus","volume":"27","author":"Lee","year":"2018","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225319_bib79","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1177\/0961203318781008","article-title":"Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort","volume":"27","author":"Spinelli","year":"2018","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225319_bib80","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10067-018-4348-z","article-title":"Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial","volume":"38","author":"Zhang","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib81","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1093\/rheumatology\/keac002","article-title":"Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus","volume":"61","author":"Kikuchi","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-225319_bib82","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10067-021-05940-z","article-title":"Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort","volume":"41","author":"Hao","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib83","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0961203319826693","article-title":"Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort","volume":"28","author":"Alarc\u00f3n","year":"2019","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225319_bib84","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus International collaborating clinics (SLICC) inception cohort","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225319_bib85","doi-asserted-by":"crossref","first-page":"e13909","DOI":"10.1111\/ijcp.13909","article-title":"Long-term remission in patients with systemic lupus erythematosus","volume":"75","author":"Nikfar","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1136\/ard-2023-225319_bib86","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1007\/s10067-020-05379-8","article-title":"Clinical characteristics of systemic lupus erythematosus patients in long-term remission without treatment","volume":"39","author":"Jakez-Ocampo","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib87","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib88","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/S2665-9913(19)30048-7","article-title":"Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib89","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/rheumatology\/keaa407","article-title":"Comparison of three different definitions of low disease activity in patients with systemic lupus erythematosus and their prognostic utilities","volume":"60","author":"Kang","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-225319_bib90","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/acr.23867","article-title":"Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus","volume":"72","author":"Sharma","year":"2020","journal-title":"Arthritis Care & Research"},{"key":"10.1136\/ard-2023-225319_bib91","doi-asserted-by":"crossref","first-page":"e000616","DOI":"10.1136\/lupus-2021-000616","article-title":"LLDAS (lupus low disease activity state) and\/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily mestizo population: data from the almenara lupus cohort","volume":"9","author":"Ugarte-Gil","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-225319_bib92","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.40571","article-title":"Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort","volume":"70","author":"Petri","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib93","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/acr.24086","article-title":"Treatment target in newly diagnosed systemic lupus erythematosus: the Association of lupus low disease activity state and remission with lower accrual of early damage","volume":"72","author":"Floris","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2023-225319_bib94","doi-asserted-by":"crossref","first-page":"e000234","DOI":"10.1136\/lupus-2017-000234","article-title":"Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? real-life data from a monocentric cohort","volume":"5","author":"Tani","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-225319_bib95","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-022-02756-3","article-title":"Not at target\u201d: prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study","volume":"24","author":"Kandane-Rathnayake","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-225319_bib96","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/acr.23720","article-title":"Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus","volume":"71","author":"Tselios","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2023-225319_bib97","doi-asserted-by":"crossref","first-page":"e002701","DOI":"10.1136\/rmdopen-2022-002701","article-title":"Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study","volume":"8","author":"Floris","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-225319_bib98","doi-asserted-by":"crossref","first-page":"e000682","DOI":"10.1136\/lupus-2022-000682","article-title":"Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis","volume":"9","author":"Nakai","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-225319_bib99","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/rheumatology\/keac225","article-title":"Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal","volume":"62","author":"Ji","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-225319_bib100","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/acr2.11267","article-title":"Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus","volume":"3","author":"Tselios","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib101","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/09612033211002269","article-title":"Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study","volume":"30","author":"Fasano","year":"2021","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225319_bib102","doi-asserted-by":"crossref","first-page":"e000916","DOI":"10.1136\/rmdopen-2019-000916","article-title":"Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience","volume":"5","author":"Tani","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-225319_bib103","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s10067-018-4377-7","article-title":"Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre","volume":"38","author":"Goswami","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2023-225319_bib104","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1007\/s10067-019-04633-y","article-title":"Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations","volume":"38","author":"Hanaoka","year":"2019","journal-title":"Clin Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-225319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:51:52Z","timestamp":1739523112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724665428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":104,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0003496724665428"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-225319","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-225319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 European Alliance of Associations for Rheumatology, EULAR 2024. Re-use permitted under CC BY-NC-ND. No commercial re-use. No derivatives. See rights and permissions. Published by Elsevier Inc on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}